Abstract 2935
Background
Overall survival (OS) has become the definitive endpoint in oncology clinical trials, but may be difficult to assess due to need for lengthy follow-up, factors related to trial design or impacted by study crossover. Progression free survival (PFS) is a common primary endpoint, but, differential response to subsequent therapy may affect the correlation of PFS and OS. The European Medicines Agency encourages the use of PFS2, defined as time from initial study randomization to 2nd disease progression or death from any cause. The surrogacy of PFS2 for OS has not been confirmed. This analysis used published data from solid tumor clinical studies to assess whether PFS2 and OS are correlated.
Methods
A systematic literature search identified solid tumor oncology studies that included data for PFS, PFS2, and OS. Two independent reviewers screened titles, abstracts and main-text of study reports for eligibility, and collected data on median time to PFS2, PFS or time from 1st progression to 2nd disease progression or death, and median time to OS. The correlation between PFS2 and OS was assessed and verified in two steps: (1) Kendall’s Tau (Kendall rank correlation coefficient) statistics and Pearson’s correlation coefficient in randomized controlled trials (RCTs); (2) Meta-analysis with the random effects model to compute the pooled correlation of PFS2 and OS.
Results
In total, 133 studies met the search criteria and 15 trials had complete PFS2 and OS data (28 individual treatment and control arms) in ovarian, gastric, colorectal, prostate, lung, renal and breast tumors. A positive correlation was observed between PFS2 and OS (Kendall’s Tau = 0.7 (95% CIs 0.54, 0.78) using all 15 studies. Data from the 10 RCTs showed a Pearson’s correlation coefficient = 0.86. An additional meta-analysis of 3 tumors (breast, colorectal, and lung cancer), where more than 1 study per indication was available (7 studies; 17 individual arms), identified a Spearman’s correlation coefficient = 0.84 (p = 0.0001; 95% CIs 0.71, 0.96).
Conclusions
In this retrospective analysis in solid tumors, PFS2 was positively correlated with OS. The strong correlation provides confidence in using PFS2 as a surrogate for OS before OS data are mature or when OS cannot be assessed.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Ann C Sherwood, PhD with funding from Janssen Pharmaceuticals.
Legal entity responsible for the study
Janssen Pharmaceuticals.
Funding
Janssen Pharmaceuticals.
Disclosure
P.N. Mainwaring: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Licensing / Royalties: XING Technologies P/L; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer. L. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. S.D. Mundle: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. K. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. E. Pollozi: Shareholder / Stockholder / Stock options, Full / Part-time employment: IDEA Pharma; Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer; Advisory / Consultancy: Janssen. A. Gray: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: IDEA Pharma; Advisory / Consultancy: Janssen. M. Wildgust: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract